Arrowhead pharmaceuticals requests regulatory clearance to initiate phase 1/2a study of aro-alk7 for the treatment of obesity

Pasadena, calif.--(business wire)---- $arwr--arrowhead pharmaceuticals, inc. (nasdaq: arwr) today announced that it has filed a request for regulatory clearance to initiate a phase 1/2a clinical trial of aro-alk7, the company's second investigational rna interference (rnai) therapeutic being developed as a potential treatment for obesity. aro-alk7 is the first rnai-based therapy to directly target a gene expressed in adipose tissue and highlights arrowhead's leadership in the delivery of sirna to multipl.
ALK Ratings Summary
ALK Quant Ranking